Qilu Pharmaceutical's Class 2.2 new drug "Montelukast Sodium Oral Dissolving Film" was the first to be approved

On March 11, the official website of the State Food and Drug Administration showed that the 2.

Montelukast sodium is a potent and selective leukotriene receptor antagonist (trade name: Shun Erning) developed by Merck, which can specifically inhibit cysteinyl leukotriene receptors in the airway, thereby Play a role in improving airway inflammation and effectively controlling asthma symptoms.

According to the Insight database, at present, the original research has approved 3 dosage forms in the country, including ordinary tablets, chewable tablets, and granules, and all three dosage forms have been approved for generic drugs.

Oral instant film is a new type of oral preparation.

Public data shows that montelukast's sales in domestic public medical institutions in 2019 were close to 3 billion yuan.

According to the Insight database, Qilu Pharmaceutical currently has a number of oral dissolving membrane products under development.

With such fierce competition for generic drugs in China, it may be a good choice to explore new and improved drugs that are more suitable for patients.